Penumbra Q3 revenue beats estimates on thrombectomy growth
PEN•Penumbra's third-quarter revenue rose 15.6% to $410.15 million, above analysts' $403.35 million estimate, while net income declined year over year to $42.28 million. Global thrombectomy revenue increased 18.1%.
1. Revenue and earnings
Penumbra reported third-quarter revenue of $410.15 million, up 15.6% year over year and above the $403.35 million analyst consensus. Net income was $42.28 million, down from a year earlier.
2. Revenue drivers and outlook
Global thrombectomy revenue rose 18.1%, including 26% growth in U.S. venous thromboembolism revenue. Global embolization and access revenue increased 10.8%, while U.S. neuro revenue grew 19.3%. The company will not provide full-year 2026 financial guidance because of a pending acquisition.
